Lung cancer is a leading cause of cancer deaths among both men and women, and non-small-cell lung cancer (NSCLC) accounts for 80% of lung cancer cases 1 . Although recent advances have furthered the understanding of lung cancer pathogenesis, the survival rate of patients has not improved significantly 2 . Therefore, much effort has been focused on identification of new diagnostic markers and molecules involved in the disease development that could become targets for new therapeutic strategies.
MiR-126 has been reported to be delivered to the tumour environment 5 . We and others have shown that during cancer progression, miR-126 is down-regulated, with ensuing changes in the expression and activity of metabolism-related factors [11] [12] [13] [14] [15] . MiR-126 is an endothelial-specific miR, which is expressed at low levels in NSCLC patients 12, 16, 17 , and its re-expression inhibits cell proliferation in vitro and tumour growth in vivo by targeting EGFL7 18 . Given that circulating miRs are differentially regulated and selectively packaged in exosomes, we evaluated the distribution of miR-126 in the circulation of NSCLC patients at early and advanced stages of the disease, and compared the level of the miR with healthy subjects. We then examined the possibility that exo-miR-126 discriminates NSCLC patients at different stages from controls, as well as that it affects tumour formation and progression.
Results

Levels of miR-126 in serum compartments of NSCLC patients. From March 2015 to March 2017, 45
patients with NSCLC and 31 control subjects (CTRL) were enrolled. According to the 7 th lung cancer TNM classification, NSCLC patients have been included in three stage groups: Stage I group (TIaN0, TIbN0, TIIaN0), Stage II group (TIaN1, TIIbN0, TIIbN1, TIIIN0, TIIINxMx), Stage III/IV group (TIIbN2, TIVN0, TIIIN2, TIaN2, TIbN2, TIIaN2, TIIbN2, TxN3M0, TIVN0M1b, TIIIN0M1a, TIIINxM1a). The demographic characteristics are summarized in Table 1 . Initially, exosomes were isolated from serum of the subjects and their level in the circulation of patients of various tumour stages evaluated by several methods. Isolated exosomes were visualized by transmission electron microscopy (TEM), their size distribution was evaluated using nanoparticle tracking analysis (NTA) technology, and the concentration was estimated by the number of particles and exosomal protein level. The presence of CD81, a specific exosome marker, was confirmed by western blotting. The size distribution based on the NTA analysis was in agreement with the microscopy images. Based on the particle number, protein and CD81 levels, advanced NSCLC patients (Stage III/IV group) showed higher levels of circulating exosomes compared to other groups (Fig. 1A,B) . On the other hand, no relevant differences in concentration, size and number of exosomes between healthy subjects and early stage NSCLC patients (Stage I/II groups) were observed ( Fig. 1C-E ).
We next studied the level of miR-126 in three compartments: total serum, exosomes (exo), and exosome-free serum (exo-free serum), in the study groups (CTRL and NSCLC-Stage I, Stage II, Stage III/IV groups). We found that at early stages, the level of serum miR-126 was comparable in early NSCLC patients and control subjects, while it was significantly down-regulated in advanced NSCLC patients ( Fig. 2A ). Both at early and advanced stages, miR-126 was mainly present in exosomes (Fig. 2B) . The increased level of miR-126 in exosomes paralleled the decrease of miR-126 content in the exosome-free serum fraction (Fig. 2C) . The distribution of miR-126 in the exosomal and extra-exosomal compartments was also evaluated. As shown in Fig. 2D , the miR-126 exo-free serum / miR-126 serum ratio decreased in NCSLC compared to healthy controls with a significant low ratio value at late stage, thus suggesting that at this stage miR-126 was encapsulated within exosomes rather than associated with circulating proteins.
Exosomal miR-126 as a circulating biomarker for NSCLC progression. The different distribution of exo-miR-126 in the serum from cancer patients versus healthy individuals has revealed important differences in relation to tumour progression, highlighting a possible use of this miR as a disease biomarker. Therefore, the NSCLC Patients (n = 45) Control subjects (n = 31) mean ± SD % mean ± SD % performance of circulating miR-126 to distinguish patients affected by NSCLC at different stages of disease progression from controls was evaluated. The ROC analysis shows that serum miR-126 differentiated neither controls from NSCLC patients in general nor NSCLC at early stages, while discriminating the disease at advanced stage. Notably, exo-miR-126 significantly discriminated NSCLC patients at early from those at advanced tumour stages ( Fig. 3A-C) .
Exo-miR-126 from endothelial cells suppresses NSCLC tumorigenic function. has been reported to act as a tumour suppressor and metastasis inhibitor in cancer, while inducing cell proliferation and angiogenesis in non-tumorigenic cells 19 . It was observed that exosome secretion maintains cellular homeostasis by removing toxic DNA fragments from cells 20 . Therefore, we can hypothesize that cancer cells may eliminate miR-126 via the exosomal pathway, with ensuing uptake of miR by recipient cells to induce distal transformation and angiogenesis, promoting cancer progression. To address these hypothesizes, NSCLC-derived exosomes (exo-NSCLC) were incubated with non-tumorigenic epithelial and endothelial cells, and proliferation, transformation and vessel formation were evaluated. As shown in Fig. 4A , exosomes from NSCLC patients were taken up at high rates by the recipient BEAS-2B cells, eliciting their decreased proliferation with concomitant transformation (Fig. 4B) . Further, exo-NSCLC induced angiogenesis, which was inhibited by specific anti-miR, supporting the role of miR-126 in the regulation of this process (Fig. 4C) .
MiR-126 is highly expressed in endothelial cells, and endothelial-derived exosomes contain high levels of miR-126 21 . Therefore, endothelial-derived exosomes isolated from human umbilical vein endothelial cells (HUVECs) (HUVEC exosomes), and miR-126-enriched exosomes from HUVECs cultured under condition of glucose deprivation, were incubated with NSCLC cells, and exosome uptake, miR-126 content, and expression of its targets were evaluated. In addition, proliferation rates of NSCLC cells and malignancy following exosome treatment were also investigated. Uptake of exosomes by NSCLC recipient cells was observed after 4 h incubation with HUVEC exosomes previously stained with acridine orange (Fig. 5A ). We found that exosomes readily interacted with The ratio of circulating miR-126 in exosomes-free serum and serum of CTRL subjects and NSCLC patients at different tumour stages is shown. Statistical analyses were performed using one-way analysis of variance (ANOVA), with Tukey post-hoc analysis. The symbol "*" indicates significant differences compared to control with p < 0.05. NSCLC A549 cells, leading to increased miR-126 level in malignant cells, which was related to the exosomal content of miR-126 (Fig. 5B, insert) . Increased miR-126 was accompanied by suppression of miR-126 targets, such as IRS1 and VEGF, which were restored by anti-miR treatment. On the other hand, SOXO2 and EGFL7 were not affected by HUVEC exosomes (Fig. 5B ). As shown in Fig. 5C , HUVEC exosomes significantly inhibited cancer cell proliferation independently of their miR-126 levels, and reduced colony formation and growth in soft agar (Fig. 5D ).
Discussion
Tumour cells secrete exosomes to modify the local microenvironment, which then promotes intercellular communication and metastasis. During stromal microenvironment remodelling, endothelial cells (ECs) are activated from a quiescent state leading to pathological angiogenesis 21 . MiR-126 has been reported to be mainly produced Biomarker performance in patients with NSCLC. Receiver-operating analysis of miR-126 detected in serum, exosomes and exosome-free serum. The areas under the receiver operating curves (AUC) were generated using miR-126 expression in serum, exosomes and exosome-free serum, discriminating healthy subjects (CTRL) from NSCLC patients at early (NSCLC-S-I/II) and advanced stages (NSCLC-S-III/IV). Differences with p < 0.05 were considered statistically significant. by ECs, delivered to the surrounding tumour milieu, and to regulate angiogenesis 16, 22 . As previously found, a significant reduction of serum miR-126 was observed at advanced stages of tumour formation 12, 14 . Similar results were observed by Lin et al., showing that miR-126 level was stable at the early stages of NSCLC, while it was significantly down-regulated at Stage IV, suggesting a link to metastasis formation 17 . Others found low levels of circulating miR-126 both at early and advanced stages of the neoplasia [23] [24] [25] , indicating that the method of normalization used may affect the results. Here, we found an increase of exosomal miR-126 in NSCLC patients both at early and late stages of the disease (cf Fig. 2) as previously found 26 . NSCLC tumours eliminate miR-126 by exosome, thus altering the pattern of distribution of miR-126 in circulation.
Multiple cell types secrete exosomes. It this may be difficult to discern the cellular origin of miR-126-loaded exosomes. There is a hypothesis that tumour cells use exosomes to transport genetic information including miRs to surrounding cells, whereby supporting tumour growth and progression 27 . Therefore, pathological conditions can promote characteristic changes to the vesicle cargo and contribute to secretion of miR-126-enriched exosomes into circulation. MiR-126 has been widely reported as a tumour suppressor in lung cancer due to targeting IRS1, EGFL7, Crk, and SLC7A513
18 , or by means of inhibiting angiogenesis and lung metastasis during lung cancer 28, 29 . Therefore, it is not surprising that the extracellular imbalance observed can be triggered by tumour cells to drive the progression of neoplasia.
The different exosomal levels of miR-126 between NSCLC patients and controls suggests its role as a biomarker of the disease progression. In the present study, we found that exo-miR-126 differentiated healthy controls and NSCLC patients even at early stages, more significantly that with respect to miR-126 detected in serum (cf Fig. 3 ), supporting its use as a biomarker for NSCLC patients to detect the malignancy in its early stages. This is consistent with the notion that exo-miRNAs have recently emerged as potentially promising diagnostic and prognostic biomarkers in cancer and other diseases 30 . Recently, serum-derived exo-miRs such as exo-miR-21 and exo-miR-155 were found to be significantly upregulated in serum exosomes in recurrent NSCLC-bearing animals vs. non-tumour-or primary tumour-bearing animals 31 . Moreover, exosome-encapsulated miR-21 was significantly increased in patients with oesophageal squamous cell carcinoma, correlating with advanced tumour stage, positive lymph node status and metastasis 32 . Thus, exo-miRs hold considerable promise as vehicles for diagnosis of cancer and, potentially, for its management.
Exosomes play an important role in intercellular communication by acting as natural carriers of biologically active molecules between cells, thus modulating and reprogramming recipient cells. Tumour-derived exosomes function as pro-tumorigenic factors that can mediate intercellular communication in the tumour microenvironment and can also contribute to cancer progression 33 . Here, we demonstrated for the first time that transfer of exosomal cargo from patients affected by NSCLC at early and advanced stages of the disease made the tumour microenvironment beneficial for cancer cells, inducing distal malignant transformation and angiogenesis (cf Fig. 4) . Consistent with this, exosomes from pleural effusion of malignant mesothelioma (MM) patients have been shown to modulate the angiogenic and metastatic potential of mesothelioma cells 34 . Further, exosomes from serum of breast cancer patients, but not those from healthy controls, were shown to induce transformation of non-tumorigenic epithelial cells, suggesting a potential role for exosome in tumorigenesis 35 . As observed previously in MM, we show here that NSCLC-derived exosomes carrying high levels of miR-126 significantly enhanced HUVEC tube formation compared to the vehicle control. Silencing of miR-126 by anti-miR markedly suppressed angiogenesis, further supporting its role in vessel formation. Intriguingly, miR-126 is thought to possess dual angiogenesis regulatory properties. On one hand, it can inhibit angiogenesis and maintain the quiescent endothelial phenotype. On the other hand, upregulation of miR-126 can activate endothelial progenitor cells (EPCs) and ECs, contributing to formation of new blood vessels by a mechanism that involves SPRED1 inhibition 36 . However, despite the pro-angiogenic role of miR-126, other factors delivered by exosome, such as EGFR, may induce vessel formation 20, 37 . The ability of exosomes to transport functionally active cargo, thus affecting recipient cells, might be used as a tool in cancer therapy. Therefore, we exposed cancer cells to exosomes from ECs (HUVECs) carrying miR-126, and have found that the tumour-suppressive miR-126 secreted from ECs could be taken up by recipient cancer cells, exerting angiogenic and cancer cell growth inhibitory function (cf Fig. 5 ). EC-derived miR-126 was found compartmentalised mainly to circulating exosomes. Certain cells, such as cardiomyocytes, increase their exosome secretion under glucose starvation conditions. Moreover, cardiomyocytes-derived exosomes modulate their miR cargo in a glucose-dependent manner. In vitro experiments revealed that hyperglycemia reduces packaging of miR-126 into endothelial microparticles 38 , while glucose starvation induces miR-126-enriches exosome formation 39 . Consistent with the above notion, we found that exosomes derived from HUVECs cultured under glucose deprivation had increased miR-126 levels. MiR-126-enriched exosomes were shown to be transported into recipient cancer cells, where they regulated the downstream targets IRS1 and VEGF, inhibiting cell growth and transformation. Neither EGFL7 nor SOX2 genes were affected by miR-126. Although miR-126 is strictly expressed in ECs and excised from the EGFL7 pre-mRNA, its expression does not affect splicing and expression of its 'host' gene 40 . Recently, it has become clear that exo-miRs play a critical role in mediating cell-to-cell communication, particularly between ECs and cancer cells 39 . Upon release of their functionally active miR load inside the recipient cell, exosomal cargo can regulate gene expression via de novo translation and post-translational regulation of target mRNAs 8 . Several studies confirmed the presence of horizontal transfer of miRNAs via exosomes derived (exo-NSCLC Stage III/IV) stages were evaluated by counting the number of complete tubes connecting points of individual polygons of the capillary network in a light microscope at 24 h (lower panel). The data and images are relative of three independent experiments. Comparisons among groups were determined by one-way ANOVA with Tukey post-hoc analysis. The symbol "*" indicates significant differences compared with control, and the symbol "°" indicates significant between CTRL and anti-miR, with p < 0.05.
SCIenTIFIC RepoRts | 7: 15277 | DOI:10.1038/s41598-017-15475-6 from tumours [41] [42] [43] . MiRs transferred by exosomes are emerging as novel regulators of cellular function, which can be used for cancer therapy. In this context, it was found that intra-tumour injection of exosomes derived from miR-146-expressing mesenchymal stem cells significantly reduced glioma xenograft growth in a rat model of primary brain tumour 44 . Another study reported that exosome-derived miR-302b significantly suppressed lung cancer cell proliferation and migration via the TGFβRII/ERK pathways, pointing to a potential target for lung cancer therapy 45 . Therefore, exosome-delivered miRs hold a substantial promise to present efficacious personalized therapeutic modalities given their use in biomarker discovery and personalized diagnostics. 
Materials and Methods
Study population. Venous blood was collected in anti-coagulant-free tubes from NSCLC patients and healthy controls. NSCLC patients (n = 45) were recruited in the Oncology Clinic of the University Hospital of Ancona, Italy. Pathologic diagnosis was performed on pleural biopsies obtained by thoracoscopy or thoracotomy. Classification of tumour stages was based on the 7 th lung cancer TNM grading. The tumours were classified as squamous cell carcinomas (30%), adenocarcinomas (59%), and large-cell lung carcinoma (11%). Exclusion criteria were the presence or suspicion of an infectious disease, previous radical surgery, radiotherapy, as well as chemotherapy. The control group consisted of 31 healthy subjects recruited at the Clinic of Occupational Medicine, Polytechnic University of Marche, Ancona, Italy. Whole blood was centrifuged at 3,000 × g for 10 min, and aliquots of serum were collected and immediately frozen at −80 °C. All subjects filled a questionnaire including their informed consent. The study was carried out according to the Helsinki Declaration and the samples were processed under approval of the written consent statement and all experimental protocols were approved by Ethical Committee of the University Hospital of Marche, N. 51/DG 05/02/2009, Ancona, Italy.
Preparation of exosomes and exosome-free serum fraction. HUVEC-derived exosomes enriched in miR-126 were obtained by culturing HUVEC cells in glucose-deprived media for 48 h as previously described 40 . Exosomes were isolated from serum and HUVEC in exosome-depleted serum culture medium 16 . Briefly, 10 ml serum (1:5 in PBS) or 10 ml of HUVEC exosome-depleted serum culture medium were thawed on ice and centrifuged at 10,000 × g for 30 min at 4 °C to remove apoptotic bodies and cellular debris. After this step, the supernatant was centrifuged at 1.6 ml of 30% sucrose/D 2 O cushion (density, 1.210 g/cm 3 ) at 100,000 × g for 40 min. The resulting supernatant (referred to as exosomes-free serum) was collected and frozen at −80 °C until analysis. The cushion was washed in PBS and centrifuged at 100.000 × g for 70 min. Subsequently, the pellet (exosomal fraction) was collected, re-suspended in 200 µl of PBS and stored at −80 °C for further use. All ultracentrifugation steps were performed at 4 °C in a Beckton Dickinson ultracentrifuge with TLS-55 swinging bucket rotor. After isolation, exosomes were re-suspended in PBS, treated with 0.1 mg/ml RNase A (Qiagen) for 1 h at 37 °C to remove miR contamination, and filtered using a 0.22 μm filter before use. Protein content of purified exosomes was determined by the Bradford assay with the Bio-Rad Protein Assay Reagent (BioRad Laboratories). Exosome concentration and size distribution were determined by the NanoSight NS300 instrument. Samples were processed in duplicates and diluted with PBS to give a range of concentrations between 10 8 -10 9 particles/ml. Samples were recorded using a camera level of 13 (camera shutter speed; 15 ms and camera gain; 350). The captured videos (60 s) were analysed using the NTA (V2.3) software (default settings) to yield particle size and concentration measurements. For in vitro treatments a pool (n = 4) of exosomes isolated from NSCLC patients at early (exo-NSCLC-Stage-I/II) and advanced (exo-NSCLC-Stage-III/IV) stages, and from control subjects (exo-CTRL) were used.
Transmission electron microscopy (TEM).
Exosomes in suspension were fixed with an equal volume of 2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) and observed via TEM after negative staining conducted as follows: a drop (~20 µl) of the sample was left to adsorb for 1 min on a 300 mesh nickel grid coated with formvar/carbon film. The sample was then contrasted with 4 steps of drops of uranyl acetate in 3% water for 30 s. The grids were air-dried and samples observed with the CM10 electron microscope (Philips) at working voltage of 80 KV. The images of the samples were recorded by the CCD camera Veleta 130.000X, and the magnification of their diameters, expressed in nanometers, were estimated using the iTEM software (TEM Imaging Plaatform, Olympus).
Western blotting. For immunoblotting, exosomes (10 µg protein) were resolved using 4-12% SDS-PAGE (Life Technologies), transferred to nitrocellulose membranes, and incubated overnight with anti-CD81 (generously provided by Prof. Fabio Malavasi, University of Torino, Torino, Italy). Actin (Bethyl) was used as loading control. After incubation with an HRP-conjugated secondary IgG (Sigma), the blots were developed using the ECL detection system (Pierce Biotechnology). Intensities of the individual bands were visualized by ChemiDoc using the Quantity One software (BioRad).
Circulating miR-126 assay. MiR-126 was detected as previously described 12 . Circulating RNA was isolated by adding to 250 µL of diluted serum (1:10), exosomes-free serum (250 µl) and exosomes (20 µg protein) fractions, 750 µl of Tri-Reagent BD (Sigma); the phase lock gel (Eppendorf) was used to improve RNA recovery. To allow for normalization of sample-to-sample variation in the RNA isolation procedure, 10 μl of synthetic Caenorhabditis elegans miR (cel-miR-39) from a 6 fmol/μl stock solution was added into the denaturing solution. The miRs were further purified from total RNA using the miR isolation kit (PureLink miRNA Isolation Kit, Thermo Fisher Scientific). MiRs were eluted in the final volume of 40 μl. Reversetranscription was achieved using individual TaqMan miR Assay, and the expression quantified by qRT-PCR. To normalize the expression levels of target miR, the U6 small nuclear RNA was used as a control. Both the endogenous (U6 small nuclear RNA) and exogenous control (cel miR-39) were used for normalization and expression as 2 −∆Ct (endog + exog).
Quantitative RT-PCR analysis (qRT-PCR).
Total RNA from cells was obtained using the RNeasy Mini Kit (Qiagen). The qPCR analysis of mRNA was performed using primers for IRS1, VEGF-1, SOX2 and EGFL7, and SYBR-select master mix (Life Technologies). GAPDH was used as the housekeeping gene. The qRT-PCR assays were performed using the Mastercycler EP Realplex (Eppendorf). The results were expressed as ΔCt, and fold changes in relative mRNA expression were calculated using the equation 2 −Δ(ΔCt) .
